P
67.95
2.17 (3.30%)
| Previous Close | 65.78 |
| Open | 66.13 |
| Volume | 178,892 |
| Avg. Volume (3M) | 160,015 |
| Market Cap | 751,504,192 |
| Price / Book | 14.50 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -2.08 |
| Total Debt/Equity (MRQ) | 23.67% |
| Current Ratio (MRQ) | 8.84 |
| Operating Cash Flow (TTM) | -16.51 M |
| Levered Free Cash Flow (TTM) | -5.43 M |
| Return on Assets (TTM) | -18.40% |
| Return on Equity (TTM) | -89.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Palvella Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
|
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company’s lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company’s patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 22.87% |
| % Held by Institutions | 47.68% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sectoral Asset Management Inc | 30 Jun 2025 | 95,615 |
| Clio Asset Management Llc | 30 Jun 2025 | 91,508 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 95.00 (HC Wainwright & Co., 39.81%) | Buy |
| Median | 82.50 (21.41%) | |
| Low | 54.00 (Raymond James, -20.53%) | Buy |
| Average | 80.88 (19.03%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 55.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 09 Oct 2025 | 90.00 (32.45%) | Buy | 70.09 |
| 19 Aug 2025 | 66.00 (-2.87%) | Buy | 48.50 | |
| Truist Securities | 02 Oct 2025 | 80.00 (17.73%) | Buy | 62.63 |
| 21 Jul 2025 | 56.00 (-17.59%) | Buy | 31.00 | |
| Chardan Capital | 26 Sep 2025 | 73.00 (7.43%) | Buy | 59.59 |
| 15 Aug 2025 | 60.00 (-11.70%) | Buy | 47.30 | |
| HC Wainwright & Co. | 25 Sep 2025 | 95.00 (39.81%) | Buy | 57.69 |
| 15 Aug 2025 | 75.00 (10.38%) | Buy | 47.30 | |
| Stifel | 24 Sep 2025 | 80.00 (17.73%) | Buy | 58.87 |
| Oppenheimer | 09 Sep 2025 | 85.00 (25.09%) | Buy | 56.71 |
| Raymond James | 06 Aug 2025 | 54.00 (-20.53%) | Buy | 39.07 |
| LifeSci Capital | 04 Aug 2025 | 90.00 (32.45%) | Buy | 37.20 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |